valine has been researched along with quinapril in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Endlich, K; Steinhausen, M | 1 |
| Shimoni, Y | 1 |
| Aljada, A; Dandona, P; Garg, R; Ghanim, H; Hofmayer, D; Kumar, V; Mohanty, P; Syed, T; Tripathy, D | 1 |
| Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Nasonova, SN; Skvortsov, AA; Sychev, AV | 1 |
| Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Nasonova, SN; Orlova, IaA; Skvortsov, AA; Sychev, AV | 1 |
| Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Nasonova, SN; Skvortsov, AA; Sychev, AV | 2 |
5 trial(s) available for valine and quinapril
| Article | Year |
|---|---|
Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blotting, Western; C-Reactive Protein; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Proteins; Isoquinolines; Leukocytes; Male; Monocytes; Neutrophils; NF-kappa B; Quinapril; Reactive Oxygen Species; Simvastatin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2003 |
[Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect o
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Renin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2005 |
[Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADK
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiac Output, Low; Chronic Disease; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling | 2006 |
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; Drug Therapy, Combination; Electrocardiography, Ambulatory; Follow-Up Studies; Heart Failure; Humans; Quinapril; Severity of Illness Index; Stroke Volume; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; Drug Therapy, Combination; Electrocardiography, Ambulatory; Exercise Test; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Quinapril; Stroke Volume; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
2 other study(ies) available for valine and quinapril
| Article | Year |
|---|---|
Role of kinins and angiotensin II in the vasodilating action of angiotensin converting enzyme inhibition in rat renal vessels.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Bradykinin Receptor Antagonists; Drug Synergism; Female; Isoquinolines; Kidney; Kinins; Quinapril; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Renin-Angiotensin System; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan; Vasodilation | 1997 |
Inhibition of the formation or action of angiotensin II reverses attenuated K+ currents in type 1 and type 2 diabetes.
Topics: Action Potentials; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Electric Conductivity; Isoquinolines; Mutation; Potassium Channels; Quinapril; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Angiotensin, Type 2; Receptors, Cell Surface; Receptors, Leptin; Saralasin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2001 |